Grossi, C.E. , Cliffton, E.E., AND Can-Namela , D.: The lysis of intravascular thrombi in rabbits with human plasmin (fibrinolysin). Blood , 9: 310, 1954.
2.
Grossi, C.E. , AND Cliffton, E.E.: The lysis of arterial thrombi in rabbits and dogs by use of activated human plasminogen (fibrinolysin (plasmin)) . Surgery, 37: 794, 1955.
3.
Back, N., Ambrus, J.L., Byron, J.W., AND Shulman, S.: Effect of delayed treatment with plasmin (fibrinolysin) on thrombi produced with I131 labelled fibrinogen. Circulation Res.,4: 440, 1956.
4.
Ambrus, J.L. , Ambrus, C.M., Sokal , J.E., Markus, G., Back, N., Stutzman, L., Razis, D., Ross, C.A., Smith, B.H., Rekate, A.C., Collins, G.L., Kline, D.L., AND Fishman, J.B.: Clinical pharmacology of various types of fibrinolytic enzyme preparations. Am. J. Cardiol., 6: 462, 1960.
5.
Cliffton, E.E. : The use of plasmin in the treatment of intravascular thrombosis. J. Am. Geriatics Soc.,6: 118, 1958.
6.
Fletcher, A.P. , Alkjaersig, N., Sawyer , W.D., AND Sherry, S.: Evaluation of human fibrinolysin (actase) . J. A. M. A., 172: 912, 1960.
7.
Cliffton, E.E. : Fibrinolysin as an agent for treatment of thromboembolic accidents. J. A. M. A., 175: 302, 1961 .
8.
Cliffton, E.E. : Review of clinical experience with clot-lysing agents. Am. J. Cardiol., 6: 476, 1960.
9.
Cliffton, E.E. : Mechanism of formation of vascular thrombosis and its treatment with fibrinolysin. J. Nat. M. A., 53: 456, 1961.
10.
Freiman, A.H. , AND Cliffton, E.E.: Effect of fibrinogen concentration on susceptibility of clots to in vitro clot lysis with plasmin. Thromb. et Diath. Haem.,2: 269, 1958.
11.
Bang, N.U., AND Cliffton, E.E.: The effect of alimentary hyperlipemia on thrombolysis in vivo. Thromb. et Diath. Haem.,4: 149, 1960.
12.
Cliffton, E.E. : Variations in the proteolytic and antiproteolytic reactions of serum: effect of disease, trauma, x-ray, anaphylactic shock, ACTH and cortisone. J. Lab. & Clin. Med., 39: 105, 1952.
13.
Astrup, T.: Fibrinolysis in organism. Blood, 11: 781, 1956.
14.
Soulier, J.P. , Alagille, D., AND Larrieu, M.J.: In vivo and in vitro proteolysis of coagulation factors other than fibrinogen. VI Congress of International Society of Hematology, Boston, August 27 to September 1, 1956.
15.
Norman, P.S. , AND Hill, B.M.: Studies of the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma. J. Exper. Med., 108: 639, 1958.
16.
Tillett, W.S. , Edwards, L.B., AND Garner, R.L.: Fibrinolytic activity of hemolytic streptococci . J. Clin. Invest., 13: 47, 1934.
17.
Gerheim, E.B. , AND Ferguson, J.H.: Species reactivity to staphylokinase. Proc. Soc. Exper. Biol. &Med., 71: 261, 1949.
18.
Mullertz, S. : Formation and properties of the activator of plasminogen and of human and bovine plasmin. Biochem. J. , 61: 424, 1955.
19.
Shinowara, C.Y.: Enzyme studies on human blood. I. Proteolytic activity associated with a fraction of plasma. Proc. Soc. Exper. Biol. &Med., 66: 456, 1947.
20.
Alkjaersig, N., Fletcher, A.P., AND Sherry, S.: The mechanism of clot dissolution by plasmin . J. Clin. Invest., 38: 1086, 1959.
21.
Ambrus, C.M. , AND Markus, G.: Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme. Am. J. Physiol., 199: 491, 1960 .
22.
Johnson, A.J. , AND McCarty, W.R.: Streptokinase as a thrombolytic agent. Am. J. Cardiol., 6: 487, 1960.
23.
Celander, D.R. , AND Guest, M.M.: The biochemistry and physiology of urikinase . Am. J. Cardiol., 6: 409, 1960.
24.
Meneghini, P.: Fibrinolytic treatment of thromboembolic diseases with purified bacterial pyrogens. Acta haemat.,19: 65, 1958.
25.
Von Kaulla, K.N.: Intravenous protein-free pyrogen: a powerful fibrinolytic agent in man. Circulation, 17: 187, 1958.
26.
Weiner, M., Redisch, W., AND Steele, J.M.: Occurrence of fibrinolytic activity following administration of nicotinic acid. Proc. Soc. Exper. Biol. &Med., 98: 755, 1958.
27.
Clarke, R.L. , AND Cliffton, E.E.: The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am. J. Cardiol. , 6: 546, 1960.
28.
Freiman, A.H. , Bang, N.U., Grossi , C.E., AND Cliffton , E.E.: Factors affecting the formation and dissolution of experimental thrombi. Am. J. Cardiol., 6: 426, 1960.
29.
Ruegsegger, P., Nydick, I., Abarquez , R., Reichel, F., Cliffton, E.E., AND Ladue, J.S.: Effect of fibrinolytic (plasmin) therapy on the physiopathology of myocardial infarction. Am. J. Cardiol. , 6: 519, 1960.
30.
Ruegsegger, P., Nydick, I., Hutter , R.C., Freiman, A.H., Bang, N.U., Cliffton, E.E., AND Ladue, J.S.: Fibrinolytic (plasmin) therapy of experimental coronary thrombi with alterations of the evolution of myocardial infarction . Circulation, 19: 7, 1959.
31.
Davis, N.D. , Carroll, B.J., AND Schwartz , S.H.: Treatment of thrombophlebitis with a fibrinolytic agent; with special references to side effects. Am. J. Cardiol., 6: 513, 1960.
32.
Moser, K.M., AND Hajjar, G.C.: The combined use of fibrinolytic and anticoagulant agents. Laboratory and clinical considerations. Am. J. Cardiol., 6: 496, 1960.
33.
Herndon, R.M. , Meyer, J.S., Johnson , J.F., AND Landers, J.: Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. Am. J. Cardiol., 6: 540, 1960.
34.
Sussman, B.J. , AND Fitch, T.S.: Thrombolysis with fibrinolysin in cerebral arterial occlusion. Angiology, 12: 169, 1961.
35.
Anlyan, W.G. , Deaton, H.L., AND Silver, D.: Experiences with fibrinolysin in peripheral vascular disease. Am. J. Cardiol., 6: 507, 1960.
36.
Boucek, R.J. , AND Murphy, W.P., JR.: Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction . Am. J. Cardiol.,6: 525, 1960.
37.
Fletcher, A.P. , Sherry, S., Alkjaersig , N.Smyrniotis, F.E., AND Jick, S.: The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders . J. Clin. Invest.,38: 1111, 1959.
38.
Richter, I.H. , Musacchio, F., Cliffton , E.E., Nassar, A., Kaplan, L., Favazza, A.G., AND Akbari, A.: Experiences with clot-lysing agents in coronary thrombosis. Am. J. Cardiol. , 6: 534, 1960.
39.
Cliffton, E.E. : Enzymatic treatment of infection involving bones and joints, including several with metallic prostheses. J. Bone & Joint Surg., 42: 880, 1960.
